ArticleInternational journal of hypertension2026
Differential Effects of Antihypertensive Drug Classes on Home and Office Blood Pressure Variability.
Article in International journal of hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Differential Effects of Antihypertensive Drug Classes on Home and Office Blood Pressure Variability.International journal of hypertension · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Blood pressure (BP) variability provides prognostic information beyond mean BP. However, the class-specific associations of antihypertensive medications with BP variability remain uncertain, and few studies have directly contrasted home and office BP variability within the same patients while accounting for the white-coat effect. Methods: In a multicenter prospective registry, patients with hypertension and adequate measurements (≥ 10 home and ≥ 5 office readings) were analyzed. The primary outcomes were systolic and diastolic average real variability (ARV) of home and office BP. Associations of renin-angiotensin system inhibitors, beta-blockers, dihydropyridine calcium channel blockers (DHP-CCBs), and diuretics with BP variability were estimated using inverse probability of treatment weighting (IPTW) and doubly robust models. The white-coat effect was further adjusted using both a continuous office-home mean difference and a guideline-based white-coat definition. A true-monotherapy subcohort sensitivity analysis and class-by-class interaction tests were additionally performed. Results: Among 495 participants, home ARV differed minimally by antihypertensive class; a small beta-blocker-associated increase in home systolic BP (SBP)-ARV was attenuated with additional adjustment. In contrast, office BP ARV was higher with DHP-CCBs and diuretics, although the beta-blocker association was weakened after further adjustment. Following white-coat effect adjustment, home BP ARV remained neutral across drug classes, whereas DHP-CCB remained associated with higher office SBP-ARV and diuretics with higher office diastolic BP ARV. DHP-CCBs were also associated with a lower probability of office BP control. Home BP control rates did not differ significantly by antihypertensive class. Conclusions: In this cross-sectional observational cohort, antihypertensive medication classes showed context-dependent associations with BP variability, which were minimal for home BP but more pronounced for office BP, partially independent of the white-coat effect. Given potential residual confounding by indication, these hypothesis-generating findings warrant prospective confirmation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.